NCT07793006 New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
| NCT ID | NCT07793006 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-03-17 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD). Overcoming these delays and missed diagnoses requires new approaches to identify lymphoma and MCD.
Eligibility Criteria
Inclusion Criteria: * Age ≥1 year old and body weight of ≥ 10 kg. * HIV-infected. * Unexplained lymphadenopathy with at least one lymph node ≥2 cm that is amenable to biopsy. * Willing and able to give informed consent if the subject is 18 years of age or older, adolescent assent and legal guardian consent for subjects 15-17 years of age, pediatric assent and legal guardian consent for subjects 7-14 years of age, or legal guardian consent for pediatric subjects less than 7 years of age. Exclusion Criteria: * Cannot or is not willing to follow study procedures. * Subjects with a previous history of cancer in the last five years with the exception of subjects with Kaposi sarcoma (i.e. history of Kaposi sarcoma is allowed in the study).
Contact & Investigator
Michael Painschab, MD
PRINCIPAL INVESTIGATOR
IUSCCC
Frequently Asked Questions
Who can join the NCT07793006 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07793006 currently recruiting?
Yes, NCT07793006 is actively recruiting participants. Contact the research team at mapain@iu.edu for enrollment information.
Where is the NCT07793006 trial being conducted?
This trial is being conducted at Lilongwe, Malawi.
Who is sponsoring the NCT07793006 clinical trial?
NCT07793006 is sponsored by Indiana University. The principal investigator is Michael Painschab, MD at IUSCCC. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.